Regend

Executive Summary

Regend is a Beijing-based biotechnology company pioneering regenerative medicine for respiratory diseases, with a primary focus on chronic obstructive pulmonary disease (COPD). Founded in 2020, the company leverages autologous lung progenitor cells to repair damaged lung tissue, addressing a significant unmet need in respiratory care. Currently at Phase 1 clinical stage, Regend has developed a proprietary cell therapy platform that aims to restore lung function in patients with COPD and other serious respiratory conditions. The company operates in a rapidly growing regenerative medicine market, with COPD affecting over 300 million people globally. As a private firm with 10-50 employees, Regend is positioned to capture early-mover advantage in China's evolving cell therapy landscape. While no funding details or valuation are publicly available, the company's focused pipeline and early clinical progress suggest potential for strategic partnerships or licensing deals. Future success hinges on demonstrating safety and efficacy in ongoing trials, navigating regulatory pathways, and securing capital for advanced development. With strong scientific rationale and a clear unmet need, Regend represents an early-stage opportunity in respiratory regenerative medicine.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2 clinical trial for COPD treatment40% success
• Q2 2026Publication of Phase 1 safety and efficacy data in peer-reviewed journal60% success
• Q1 2027Strategic partnership or licensing deal with a major pharmaceutical company30% success